Citation: Tianqi Wang, Yanan Fu, Shengjie Sun, Chenyi Huang, Yunfei Yi, Junqing Wang, Yang Deng, Meiying Wu. Exosome-based drug delivery systems in cancer therapy[J]. Chinese Chemical Letters, ;2023, 34(2): 107508. doi: 10.1016/j.cclet.2022.05.022 shu

Exosome-based drug delivery systems in cancer therapy

School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China

wangjunqing@mail.sysu.edu.cn

dengy67@mail.sysu.edu.cn

wumy53@mail.sysu.edu.cn

Received Date: 20 January 2022
Revised Date: 6 May 2022
Accepted Date: 10 May 2022
Available Online: 14 May 2022

Figures(4)

Exosome, which is a kind of extracellular vesicles with size around 40-160 nm, plays an important role in cell-to-cell communication in multiple diseases. Especially in tumor microenvironment, exosomes are the important pathway to transit proteins, nucleic acids and small molecules between different kinds of cells. Based on these characteristics, exosomes are served as both therapeutic agents and drug delivery systems in cancer therapy. In this review, the applications of exosomes as drug delivery systems in cancer therapy were summarized and classified according to the cell source of the exosomes, including normal cells, immune cells and tumor cells. Different modifications of exosomes and drug loading methods were presented. Finally, some challenges that hindered the clinical translation of exosomes were also discussed.
- Exosome,
- Drug delivery,
- Cancer therapy,
- Immunotherapy,
- Macrophages,
- Tumor cells
1. [1]
  R. Kalluri, V.S. LeBleu, Science 367 (2020) eaau6977. doi: 10.1126/science.aau6977
2. [2]
  D.M. Pegtel, S.J. Gould, Annu. Rev. Biochem. 88 (2019) 487–514. doi: 10.1146/annurev-biochem-013118-111902
3. [3]
  S. Keerthikumar, D. Chisanga, D. Ariyaratne, et al., J. Mol. Biol. 428 (2016) 688–692. doi: 10.1016/j.jmb.2015.09.019
4. [4]
  M. Pathan, P. Fonseka, S.V. Chitti, et al., Nucleic Acids Res. 47 (2019) D516–D519. doi: 10.1093/nar/gky1029
5. [5]
  G. Arienti, E. Carlini, R. Verdacchi, et al., Biochim. Biophys. Acta 1336 (1997) 533–538. doi: 10.1016/S0304-4165(97)00071-8
6. [6]
  L.M. Doyle, M.Z. Wang, Cells 8 (2019) 727. doi: 10.3390/cells8070727
7. [7]
  D. Yang, W. Zhang, H. Zhang, et al., Theranostics 10 (2020) 3684–3707. doi: 10.7150/thno.41580
8. [8]
  Z. Fang, X. Zhang, H. Huang, J. Wu, Chin. Chem. Lett. 33 (2022) 1693–1704. doi: 10.1016/j.cclet.2021.11.050
9. [9]
  Y. Lu, Z. Tong, Z. Wu, et al., Chin. Chem. Lett. 33 (2022) 3188–3192. doi: 10.1016/j.cclet.2021.12.045
10. [10]
  J. Wang, D. Chen, E.A. Ho, J. Control. Release 329 (2021) 894–906. doi: 10.1016/j.jconrel.2020.10.020
11. [11]
  Y. Zhang, J. Bi, J. Huang, et al., Int. J. Nanomed. 15 (2020) 6917–6934. doi: 10.2147/IJN.S264498
12. [12]
  M.N. Huda, M. Nurunnabi, Pharm. Res. 39 (2022) 2635–2671. doi: 10.1007/s11095-021-03143-4
13. [13]
  P. Gao, X. Li, X. Du, et al., Front. Aging Neurosci. 13 (2021) 790863. doi: 10.3389/fnagi.2021.790863
14. [14]
  Z.G. Zhang, B. Buller, M. Chopp, Nat. Rev. Neurol. 15 (2019) 193–203. doi: 10.1038/s41582-018-0126-4
15. [15]
  R.C. de Abreu, H. Fernandes, P.A. da Costa Martins, et al., Nat. Rev. Cardiol. 17 (2020) 685–697. doi: 10.1038/s41569-020-0389-5
16. [16]
  C.H. Chang, S. Pauklin, Cell Death Dis. 12 (2021) 973. doi: 10.1038/s41419-021-04258-7
17. [17]
  L. Zhang, D. Yu, Biochim. Biophys. Acta 1871 (2019) 455–468.
18. [18]
  V.C. Kok, C.C. Yu, Int. J. Nanomed. 15 (2020) 8019–8036. doi: 10.2147/IJN.S272378
19. [19]
  L. Cheng, A.F. Hill, Nat. Rev. Drug. Discov. 21 (2022) 379–399. doi: 10.1038/s41573-022-00410-w
20. [20]
  I. Parolini, C. Federici, C. Raggi, et al., J. Biol. Chem. 284 (2009) 34211–34222. doi: 10.1074/jbc.M109.041152
21. [21]
  W. Liao, Y. Du, C. Zhang, et al., Acta Biomater. 86 (2019) 1–14. doi: 10.1016/j.actbio.2018.12.045
22. [22]
  O.M. Elsharkasy, J.Z. Nordin, D.W. Hagey, et al., Adv. Drug Deliv. Rev. 159 (2020) 332–343. doi: 10.1016/j.addr.2020.04.004
23. [23]
  M.S. Kim, M.J. Haney, Y. Zhao, et al., Nanomedicine 12 (2016) 655–664. doi: 10.1016/j.nano.2015.10.012
24. [24]
  E.V. Batrakova, M.S. Kim, J. Control. Release 219 (2015) 396–405. doi: 10.1016/j.jconrel.2015.07.030
25. [25]
  K. Maisel, M.S. Sasso, L. Potin, M.A. Swartz, Adv. Drug Deliv. Rev. 114 (2017) 43–59. doi: 10.1016/j.addr.2017.07.005
26. [26]
  S. Srinivasan, F.O. Vannberg, J.B. Dixon, Sci. Rep. 6 (2016) 24436. doi: 10.1038/srep24436
27. [27]
  K.B. Johnsen, J.M. Gudbergsson, M.N. Skov, et al., Biochim. Biophys. Acta 1846 (2014) 75–87.
28. [28]
  S.J. Greco, P. Rameshwar, Ther. Deliv. 3 (2012) 997–1004. doi: 10.4155/tde.12.69
29. [29]
  R.W. Yeo, R.C. Lai, B. Zhang, et al., Adv. Drug Deliv. Rev. 65 (2013) 336–341. doi: 10.1016/j.addr.2012.07.001
30. [30]
  Z. Naseri, R.K. Oskuee, M.R. Jaafari, M. Forouzandeh Moghadam, Int. J. Nanomed. 13 (2018) 7727–7747. doi: 10.2147/IJN.S182384
31. [31]
  J. Wang, G. Li, C. Tu, et al., Nanoscale 12 (2020) 13742–13756. doi: 10.1039/D0NR02344B
32. [32]
  M. Zhuang, X. Chen, D. Du, et al., Nanoscale 12 (2020) 173–188. doi: 10.1039/C9NR05865F
33. [33]
  Z. Yang, J. Shi, J. Xie, et al., Nat. Biomed. Eng. 4 (2020) 69–83.
34. [34]
  A. Kabashima-Niibe, H. Higuchi, H. Takaishi, et al., Cancer Sci. 104 (2013) 157–164. doi: 10.1111/cas.12059
35. [35]
  W. Blogowski, T. Bodnarczuk, T. Starzynska, Stem. Cells Transl. Med. 5 (2016) 938–945. doi: 10.5966/sctm.2015-0291
36. [36]
  Y. Zhou, W. Zhou, X. Chen, et al., Acta Pharm. Sin. B 10 (2020) 1563–1575. doi: 10.1016/j.apsb.2019.11.013
37. [37]
  W. Zhou, Y. Zhou, X. Chen, et al., Biomaterials 268 (2021) 120546. doi: 10.1016/j.biomaterials.2020.120546
38. [38]
  G. Lou, L. Chen, C. Xia, et al., J. Exp. Clin. Cancer Res. 39 (2020) 4. doi: 10.1186/s13046-019-1512-5
39. [39]
  A. Thakur, R.K. Sidu, H. Zou, et al., Int. J. Nanomed. 15 (2020) 8331–8343. doi: 10.2147/IJN.S263956
40. [40]
  T. Vilanova-Perez, C. Jones, S. Balint, et al., Nanomedicine (Lond) 15 (2020) 1965–1980. doi: 10.2217/nnm-2020-0056
41. [41]
  X. Zhu, M. Badawi, S. Pomeroy, et al., J. Extracell. Vesicles 6 (2017) 1324730. doi: 10.1080/20013078.2017.1324730
42. [42]
  L.E. Rosas, O.A. Elgamal, X. Mo, et al., J. Immunotoxicol. 13 (2016) 652–665. doi: 10.3109/1547691X.2016.1148089
43. [43]
  Y. Si, S. Kim, E. Zhang, et al., Biotechnol. J. 15 (2020) e1900163. doi: 10.1002/biot.201900163
44. [44]
  A. Afshari, C. Uhde-Stone, B. Lu, Biochem. Biophys. Res. Commun. 448 (2014) 281–286. doi: 10.1016/j.bbrc.2014.04.108
45. [45]
  N. Duong, K. Curley, A. Brown, et al., Int. J. Nanomed. 14 (2019) 3413–3425. doi: 10.2147/IJN.S196975
46. [46]
  G. Liang, Y. Zhu, D.J. Ali, et al., J. Nanobiotechnol. 18 (2020) 10. doi: 10.1186/s12951-019-0563-2
47. [47]
  E. Cho, G.H. Nam, Y. Hong, et al., J. Control. Release 279 (2018) 326–335. doi: 10.1016/j.jconrel.2018.04.037
48. [48]
  N. Yim, S.W. Ryu, K. Choi, et al., Nat. Commun. 7 (2016) 12277. doi: 10.1038/ncomms12277
49. [49]
  H. Choi, Y. Kim, A. Mirzaaghasi, et al., Sci. Adv. 6 (2020) eaaz6980. doi: 10.1126/sciadv.aaz6980
50. [50]
  R.E. Veerman, G. Gucluler Akpinar, M. Eldh, S. Gabrielsson, Trends Mol. Med. 25 (2019) 382–394. doi: 10.1016/j.molmed.2019.02.003
51. [51]
  T. Lawrence, G. Natoli, Nat. Rev. Immunol. 11 (2011) 750–761. doi: 10.1038/nri3088
52. [52]
  A. Mantovani, S. Sozzani, M. Locati, et al., Trends Immunol. 23 (2002) 549–555. doi: 10.1016/S1471-4906(02)02302-5
53. [53]
  S.K. Biswas, A. Mantovani, Nat. Immunol. 11 (2010) 889–896. doi: 10.1038/ni.1937
54. [54]
  C.X. Li, Y. Zhang, X. Dong, et al., Adv. Mater. 31 (2019) e1807211. doi: 10.1002/adma.201807211
55. [55]
  L. Cheng, Y. Wang, L. Huang, Mol. Ther. 25 (2017) 1665–1675. doi: 10.1016/j.ymthe.2017.02.007
56. [56]
  P.P. Wang, H.H. Wang, Q.Q. Huang, et al., Theranostics 9 (2019) 1714–1727. doi: 10.7150/thno.30716
57. [57]
  G.R. Gunassekaran, S.M. Poongkavithai Vadevoo, M.C. Baek, B. Lee, Biomaterials 278 (2021) 121137. doi: 10.1016/j.biomaterials.2021.121137
58. [58]
  M.J. Haney, N.L. Klyachko, Y.L. Zhao, et al., J. Control. Release 207 (2015) 18–30. doi: 10.1016/j.jconrel.2015.03.033
59. [59]
  Y. Binenbaum, E. Fridman, Z. Yaari, et al., Cancer Res. 78 (2018) 5287–5299.
60. [60]
  E. Behzadi, H.M. Hosseini, R. Halabian, A.A.I. Fooladi, Microb. Pathog. 111 (2017) 132–138. doi: 10.1016/j.micpath.2017.08.027
61. [61]
  C. Gong, J. Tian, Z. Wang, et al., J. Nanobiotechnol. 17 (2019) 93. doi: 10.1186/s12951-019-0526-7
62. [62]
  W. Nie, G. Wu, J. Zhang, et al., Angew. Chem. Int. Ed. 59 (2020) 2018–2022. doi: 10.1002/anie.201912524
63. [63]
  M.S. Kim, M.J. Haney, Y.L. Zhao, et al., Nanomed. Nanotechnol. Biol. Med. 14 (2018) 195–204. doi: 10.1016/j.nano.2017.09.011
64. [64]
  G. Jia, Y. Han, Y.L. An, et al., Biomaterials 178 (2018) 302–316. doi: 10.1016/j.biomaterials.2018.06.029
65. [65]
  S. Li, Y. Wu, F. Ding, et al., Nanoscale 12 (2020) 10854–10862. doi: 10.1039/D0NR00523A
66. [66]
  S. Rayamajhi, T.D.T. Nguyen, R. Marasini, S. Aryal, Acta Biomater. 94 (2019) 482–494. doi: 10.1016/j.actbio.2019.05.054
67. [67]
  S.K. Wculek, F.J. Cueto, A.M. Mujal, et al., Nat. Rev. Immunol. 20 (2020) 7–24. doi: 10.1038/s41577-019-0210-z
68. [68]
  N.L. Vujanovic, Immunol. Res. 50 (2011) 159–174. doi: 10.1007/s12026-011-8228-8
69. [69]
  G. Lu, B.M. Janjic, J. Janjic, et al., J. Immunol. 168 (2002) 1831–1839. doi: 10.4049/jimmunol.168.4.1831
70. [70]
  I. Marigo, S. Zilio, G. Desantis, et al., Cancer Cell 30 (2016) 377–390. doi: 10.1016/j.ccell.2016.08.004
71. [71]
  S. Munich, A. Sobo-Vujanovic, W.J. Buchser, et al., Oncoimmunology 1 (2012) 1074–1083. doi: 10.4161/onci.20897
72. [72]
  Z. Lu, B. Zuo, R. Jing, et al., J. Hepatol. 67 (2017) 739–748. doi: 10.1016/j.jhep.2017.05.019
73. [73]
  J.M. Pitt, M. Charrier, S. Viaud, et al., J. Immunol. 193 (2014) 1006–1011. doi: 10.4049/jimmunol.1400703
74. [74]
  L. Zitvogel, A. Regnault, A. Lozier, et al., Nat. Med. 4 (1998) 594–600. doi: 10.1038/nm0598-594
75. [75]
  F. Andre, N. Chaput, N.E. Schartz, et al., J. Immunol. 172 (2004) 2126–2136. doi: 10.4049/jimmunol.172.4.2126
76. [76]
  B. Escudier, T. Dorval, N. Chaput, et al., J. Transl. Med. 3 (2005) 10. doi: 10.1186/1479-5876-3-10
77. [77]
  M. Xu, Q. Chen, J. Li, et al., J. B.U. ON. 25 (2020) 1413–1422.
78. [78]
  L. Alvarez-Erviti, Y. Seow, H. Yin, et al., Nat. Biotechnol. 29 (2011) 341–345. doi: 10.1038/nbt.1807
79. [79]
  Y. Tian, S. Li, J. Song, et al., Biomaterials 35 (2014) 2383–2390. doi: 10.1016/j.biomaterials.2013.11.083
80. [80]
  L. Xin, Y.W. Yuan, C. Liu, et al., Dig. Dis. Sci. 66 (2021) 1045–1053. doi: 10.1007/s10620-020-06262-x
81. [81]
  L. Chiossone, P.Y. Dumas, M. Vienne, E. Vivier, Nat. Rev. Immunol. 18 (2018) 671–688. doi: 10.1038/s41577-018-0061-z
82. [82]
  L. Zhu, J.M. Oh, P. Gangadaran, et al., Front. Immunol. 9 (2018) 824. doi: 10.3389/fimmu.2018.00824
83. [83]
  L. Zhu, S. Kalimuthu, P. Gangadaran, et al., Theranostics 7 (2017) 2732–2745. doi: 10.7150/thno.18752
84. [84]
  L. Lugini, S. Cecchetti, V. Huber, et al., J. Immunol. 189 (2012) 2833–2842. doi: 10.4049/jimmunol.1101988
85. [85]
  A.Y. Jong, C.H. Wu, J. Li, et al., J. Extracell. Vesicles 6 (2017) 1294368. doi: 10.1080/20013078.2017.1294368
86. [86]
  D. Han, K. Wang, T. Zhang, et al., Eur. Rev. Med. Pharmacol. Sci. 24 (2020) 5703–5713.
87. [87]
  P. Neviani, P.M. Wise, M. Murtadha, et al., Cancer Res. 79 (2019) 1151–1164.
88. [88]
  G. Wang, W. Hu, H. Chen, et al., Cancers 11 (2019) 1560. doi: 10.3390/cancers11101560
89. [89]
  R. Xu, A. Rai, M. Chen, et al., Nat. Rev. Clin. Oncol. 15 (2018) 617–638. doi: 10.1038/s41571-018-0036-9
90. [90]
  Y. Tan, X. Luo, W. Lv, et al., Cell Death Dis. 12 (2021) 547. doi: 10.1038/s41419-021-03825-2
91. [91]
  P.H.L. Tran, T. Wang, W. Yin, et al., Int. J. Pharm. 572 (2019) 118786. doi: 10.1016/j.ijpharm.2019.118786
92. [92]
  Y. Jang, H. Kim, S. Yoon, et al., J. Control. Release 330 (2021) 293–304. doi: 10.1016/j.jconrel.2020.12.039
93. [93]
  M. Morishita, Y. Takahashi, M. Nishikawa, et al., Mol. Pharm. 14 (2017) 4079–4086. doi: 10.1021/acs.molpharmaceut.7b00760
94. [94]
  W. Zhang, F. Wang, C. Hu, et al., Acta Pharm. Sin. B 10 (2020) 2037–2053. doi: 10.1016/j.apsb.2020.07.013
95. [95]
  S.E. Emam, A.S. Abu Lila, N.E. Elsadek, et al., Eur. J. Pharm. Biopharm. 145 (2019) 27–34. doi: 10.1016/j.ejpb.2019.10.005
96. [96]
  L. Zhao, C. Gu, Y. Gan, et al., J. Control. Release 318 (2020) 1–15. doi: 10.1016/j.jconrel.2019.12.005
97. [97]
  L. Xu, F.N. Faruqu, Y.M. Lim, et al., Biomaterials 264 (2021) 120369. doi: 10.1016/j.biomaterials.2020.120369
98. [98]
  C. Liu, W. Zhang, Y. Li, et al., Nano Lett. 19 (2019) 7836–7844. doi: 10.1021/acs.nanolett.9b02841
99. [99]
  T. Yong, X. Zhang, N. Bie, et al., Nat. Commun. 10 (2019) 3838. doi: 10.1038/s41467-019-11718-4
100. [100]
  H. Nie, X. Xie, D. Zhang, et al., Nanoscale 12 (2020) 877–887. doi: 10.1039/C9NR09011H
101. [101]
  J. Wolfers, A. Lozier, G. Raposo, et al., Nat. Med. 7 (2001) 297–303. doi: 10.1038/85438
102. [102]
  T.H. Tran, G. Mattheolabakis, H. Aldawsari, M. Amiji, Clin. Immunol. 160 (2015) 46–58. doi: 10.1016/j.clim.2015.03.021
103. [103]
  M. Obeid, A. Tesniere, F. Ghiringhelli, et al., Nat. Med. 13 (2007) 54–61. doi: 10.1038/nm1523
104. [104]
  W. Zhou, X. Chen, Y. Zhou, et al., Biomaterials 280 (2022) 121306. doi: 10.1016/j.biomaterials.2021.121306
105. [105]
  M. Yildirim, T.C. Yildirim, N. Turay, et al., Immunol. Lett. 239 (2021) 32–41. doi: 10.1016/j.imlet.2021.08.004
106. [106]
  C. Admyre, S.M. Johansson, K.R. Qazi, et al., J. Immunol. 179 (2007) 1969–1978. doi: 10.4049/jimmunol.179.3.1969
107. [107]
  I.K. Herrmann, M.J.A. Wood, G. Fuhrmann, Nat Nanotechnol. 16 (2021) 748–759. doi: 10.1038/s41565-021-00931-2
108. [108]
  C. Thery, K.W. Witwer, E. Aikawa, et al., J. Extracell. Vesicles 7 (2018) 1535750. doi: 10.1080/20013078.2018.1535750
1. [1]
  Menglin Zhang , Fanpeng Ran , Yun Zhang , Xiaoli Zhang , Zhigang Xu , Xiaoxiao Shi . Cyclodextrin-based nanotherapeutics: A promising strategy for enhanced cancer therapy. Chinese Chemical Letters, 2026, 37(1): 111232-. doi: 10.1016/j.cclet.2025.111232
2. [2]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
3. [3]
  Meng Sun , Jiazhen Yang , Leijiao Li , Yunhui Li , Wenliang Li , Jianxun Ding . Engineered bacteria potentiate cancer immunotherapy. Chinese Chemical Letters, 2025, 36(9): 111093-. doi: 10.1016/j.cclet.2025.111093
4. [4]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
5. [5]
  Shengyi Gong , Guoqiang Feng . Visible light-triggered NIR ratiometric fluorescent metal-free CO-releasing molecule for self-monitoring of CO delivery and effective cancer therapy. Chinese Chemical Letters, 2025, 36(7): 110409-. doi: 10.1016/j.cclet.2024.110409
6. [6]
  Yan Yu , Cailing Gan , Kun Shi , Zhongwu Bei , Yang Yu , Meng Pan , Hanzhi Deng , Zhiyong Qian . Recent advances in drug delivery systems for pulmonary fibrosis therapy. Chinese Chemical Letters, 2026, 37(1): 111596-. doi: 10.1016/j.cclet.2025.111596
7. [7]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
8. [8]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
9. [9]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
10. [10]
  Yiyao Wan , Wen Chen , Yan Yu , Meng Pan , Kun Shi , Zhiyong Qian . Biomaterial-based drug delivery systems for the therapy of malignant pleural effusion. Chinese Chemical Letters, 2026, 37(1): 111513-. doi: 10.1016/j.cclet.2025.111513
11. [11]
  Yupeng Wang , Xinxin Sun , Jianbin Shi , Zhixiao Zhang , Jin Sun , Cong Luo , Zhonggui He , Shenwu Zhang . Chain architecture-engineered artesunate nanoassemblies target LONP1 to induce oxidative damage for enhanced anti-tumor therapy. Chinese Chemical Letters, 2026, 37(1): 111609-. doi: 10.1016/j.cclet.2025.111609
12. [12]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
13. [13]
  Ruifeng Liang , Yanbei Tu , Peng Hua , Yongzhuo Huang , Meiwan Chen . ROS-responsive micelles co-loaded dexamethasone and pristimerin to restore the homeostasis of the inflammatory microenvironment for rheumatoid arthritis therapy. Chinese Chemical Letters, 2025, 36(6): 110335-. doi: 10.1016/j.cclet.2024.110335
14. [14]
  Zengchao Guo , Weiwei Liu , Tengfei Liu , Jinpeng Wang , Hui Jiang , Xiaohui Liu , Yossi Weizmann , Xuemei Wang . Engineered exosome hybrid copper nanoscale antibiotics facilitate simultaneous self-assembly imaging and elimination of intracellular multidrug-resistant superbugs. Chinese Chemical Letters, 2024, 35(7): 109060-. doi: 10.1016/j.cclet.2023.109060
15. [15]
  Haotian Shi , Yuchao Luo , Song Zhang , Meijun Zhao , Chaoyong Liu , Qing Pei , Helei Wang , Qiong Dai , Zhigang Xie , Bin Xu , Wenjing Tian . Dual-responsive nanogels with high drug loading for enhanced tumor targeting and treatment. Chinese Chemical Letters, 2025, 36(10): 110775-. doi: 10.1016/j.cclet.2024.110775
16. [16]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
17. [17]
  Yuanzheng Wang , Chen Zhang , Shuyan Han , Xiaoli Kong , Changyun Quan , Jun Wu , Wei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578
18. [18]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
19. [19]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
20. [20]
  Yixin Sun , Keke Yu , Xiuchun Guo , Lanlan Zong , Zhonggui He , Xiaohui Pu . Three-in-one reduction and acid-ignited micelles amplify antitumor efficacy via precise synergistic delivery of paclitaxel and naringenin. Chinese Chemical Letters, 2025, 36(6): 110393-. doi: 10.1016/j.cclet.2024.110393

Get Citation

PDF

XML

Metrics

PDF Downloads(29)
Abstract views(2626)
HTML views(336)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142